Efficacy and Safety of Growth Hormone Treatment in Juvenile Idiopathic Arthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

1996-03-31

Study Completion Date

2006-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Growth retardation is well known in patients with severe forms of juvenile idiopathic arthritis. Especially those who were under additional treatment with glucocorticoids for high disease activity. The hypothesis is, that treatment with growth hormone can, at leat in part, overcome growth hormone resistance state and increase final height. In a controlled study we follow patients with juvenile idiopathic arthritis with and without growth hormone treatment until final height. Additionally, we are interested in bone density development in those treated with growth hormone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy

NCT00174291

Endocrine System Diseases

TERMINATED PHASE3

Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease

NCT00511329

Arthritis, Juvenile Rheumatoid Crohn Disease

TERMINATED PHASE2/PHASE3

Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin

NCT00488124

Idiopathic Short Stature

COMPLETED PHASE2

Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)

NCT01052623

Ataxia Telangiectasia Growth Failure

UNKNOWN PHASE4

Efficacy Study of Recombinant Growth Hormone on Muscle Function in Children Long-term Treated With Glucocorticoid

NCT00813189

Chronic Disease Glucocorticoid Therapy, Response to Growth Retardation

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Growth retardation is well known in patients with severe forms of juvenile idiopathic arthritis. Especially those who were under additional treatment with glucocorticoids for high disease activity. This is the case in patients with a polyarticular and a systemic form of juvenile idiopathic arthritis. The permanent consequence is short stature at final height. Up to 30% of these patients will have a final height below the 3rd percentile, even after discontinuation of glucocorticoid treatment. The hypothesis is, that treatment with growth hormone can, at leat in part, overcome growth hormone resistance state and increase final height. In a controlled study we follow patients with juvenile idiopathic arthritis with and without growth hormone treatment until final height. From safety aspects we were interested in the effect of growth hormone on the disease activity. Additionally, we are interested in bone density development in those treated with growth hormone up to final height.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Juvenile Idiopathic Arthritis Still Disease, Juvenile-Onset

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Genotropin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Polyarticular or systemic juvenile idiopathic arthritis,
* Growth velocity below the 25th percentile and or short stature ,
* Treatment with glucocorticoids for at least the previous 6 months before inclusion,
* Prepubertal stage,
* Bone age below 10 in girls and 12 in boys,
* Growth hormone levels after stimulation with clonidine or arginine above 10 ng/ml

Exclusion Criteria

* Previous treatment with growth hormone,
* Endocrinopathy,
* Additional chronic disease beside juvenile idiopathic arthritis,
* Malignant disase,
* Chromosomal aberration or othe syndromal disease,
* Previous treatment with Oxandrolone,
* Small for gestational age,
* Elevated fasting glucose level

Minimum Eligible Age

4 Years

Maximum Eligible Age

14 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No